628 related articles for article (PubMed ID: 29656894)
1. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic S; Xu H; Litchfield K; Rowan A; Horswell S; Chambers T; O'Brien T; Lopez JI; Watkins TBK; Nicol D; Stares M; Challacombe B; Hazell S; Chandra A; Mitchell TJ; Au L; Eichler-Jonsson C; Jabbar F; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Stewart A; Xing W; Smith JC; Escudero M; Huffman A; Matthews N; Elgar G; Phillimore B; Costa M; Begum S; Ward S; Salm M; Boeing S; Fisher R; Spain L; Navas C; Grönroos E; Hobor S; Sharma S; Aurangzeb I; Lall S; Polson A; Varia M; Horsfield C; Fotiadis N; Pickering L; Schwarz RF; Silva B; Herrero J; Luscombe NM; Jamal-Hanjani M; Rosenthal R; Birkbak NJ; Wilson GA; Pipek O; Ribli D; Krzystanek M; Csabai I; Szallasi Z; Gore M; McGranahan N; Van Loo P; Campbell P; Larkin J; Swanton C;
Cell; 2018 Apr; 173(3):595-610.e11. PubMed ID: 29656894
[TBL] [Abstract][Full Text] [Related]
2. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
Turajlic S; Xu H; Litchfield K; Rowan A; Chambers T; Lopez JI; Nicol D; O'Brien T; Larkin J; Horswell S; Stares M; Au L; Jamal-Hanjani M; Challacombe B; Chandra A; Hazell S; Eichler-Jonsson C; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Jabbar F; Spain L; Lall S; Guarch R; Falzon M; Proctor I; Pickering L; Gore M; Watkins TBK; Ward S; Stewart A; DiNatale R; Becerra MF; Reznik E; Hsieh JJ; Richmond TA; Mayhew GF; Hill SM; McNally CD; Jones C; Rosenbaum H; Stanislaw S; Burgess DL; Alexander NR; Swanton C; ;
Cell; 2018 Apr; 173(3):581-594.e12. PubMed ID: 29656895
[TBL] [Abstract][Full Text] [Related]
3. Parallel evolution of tumour subclones mimics diversity between tumours.
Martinez P; Birkbak NJ; Gerlinger M; McGranahan N; Burrell RA; Rowan AJ; Joshi T; Fisher R; Larkin J; Szallasi Z; Swanton C
J Pathol; 2013 Aug; 230(4):356-64. PubMed ID: 23716380
[TBL] [Abstract][Full Text] [Related]
4. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Gerlinger M; Rowan AJ; Horswell S; Math M; Larkin J; Endesfelder D; Gronroos E; Martinez P; Matthews N; Stewart A; Tarpey P; Varela I; Phillimore B; Begum S; McDonald NQ; Butler A; Jones D; Raine K; Latimer C; Santos CR; Nohadani M; Eklund AC; Spencer-Dene B; Clark G; Pickering L; Stamp G; Gore M; Szallasi Z; Downward J; Futreal PA; Swanton C
N Engl J Med; 2012 Mar; 366(10):883-892. PubMed ID: 22397650
[TBL] [Abstract][Full Text] [Related]
5. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.
Bolck HA; Corrò C; Kahraman A; von Teichman A; Toussaint NC; Kuipers J; Chiovaro F; Koelzer VH; Pauli C; Moritz W; Bode PK; Rechsteiner M; Beerenwinkel N; Schraml P; Moch H
Eur Urol Focus; 2021 Jan; 7(1):152-162. PubMed ID: 31266731
[TBL] [Abstract][Full Text] [Related]
6. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
[TBL] [Abstract][Full Text] [Related]
7. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.
Mitchell TJ; Turajlic S; Rowan A; Nicol D; Farmery JHR; O'Brien T; Martincorena I; Tarpey P; Angelopoulos N; Yates LR; Butler AP; Raine K; Stewart GD; Challacombe B; Fernando A; Lopez JI; Hazell S; Chandra A; Chowdhury S; Rudman S; Soultati A; Stamp G; Fotiadis N; Pickering L; Au L; Spain L; Lynch J; Stares M; Teague J; Maura F; Wedge DC; Horswell S; Chambers T; Litchfield K; Xu H; Stewart A; Elaidi R; Oudard S; McGranahan N; Csabai I; Gore M; Futreal PA; Larkin J; Lynch AG; Szallasi Z; Swanton C; Campbell PJ;
Cell; 2018 Apr; 173(3):611-623.e17. PubMed ID: 29656891
[TBL] [Abstract][Full Text] [Related]
8. Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract][Full Text] [Related]
9. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
10. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Renal Cell Carcinoma.
Tippu Z; Au L; Turajlic S
Eur Urol Focus; 2021 Jan; 7(1):148-151. PubMed ID: 32007485
[TBL] [Abstract][Full Text] [Related]
12. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Jonasch E; Walker CL; Rathmell WK
Nat Rev Nephrol; 2021 Apr; 17(4):245-261. PubMed ID: 33144689
[TBL] [Abstract][Full Text] [Related]
13. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract][Full Text] [Related]
14. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.
Kouba EJ; Eble JN; Simper N; Grignon DJ; Wang M; Zhang S; Wang L; Martignoni G; Williamson SR; Brunelli M; Luchini C; Calió A; Cheng L
Mod Pathol; 2016 Nov; 29(11):1347-1357. PubMed ID: 27469331
[TBL] [Abstract][Full Text] [Related]
15. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas.
Zhu B; Poeta ML; Costantini M; Zhang T; Shi J; Sentinelli S; Zhao W; Pompeo V; Cardelli M; Alexandrov BS; Otlu B; Hua X; Jones K; Brodie S; Dabrowska ME; Toro JR; Yeager M; Wang M; Hicks B; Alexandrov LB; Brown KM; Wedge DC; Chanock S; Fazio VM; Gallucci M; Landi MT
Nat Commun; 2020 Jun; 11(1):3096. PubMed ID: 32555180
[TBL] [Abstract][Full Text] [Related]
16. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
Huang Y; Wang J; Jia P; Li X; Pei G; Wang C; Fang X; Zhao Z; Cai Z; Yi X; Wu S; Zhang B
Nat Commun; 2019 Mar; 10(1):1245. PubMed ID: 30886153
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
18. Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.
Köhn L; Svenson U; Ljungberg B; Roos G
Appl Immunohistochem Mol Morphol; 2015; 23(5):334-42. PubMed ID: 24992170
[TBL] [Abstract][Full Text] [Related]
19. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
Sankin A; Hakimi AA; Mikkilineni N; Ostrovnaya I; Silk MT; Liang Y; Mano R; Chevinsky M; Motzer RJ; Solomon SB; Cheng EH; Durack JC; Coleman JA; Russo P; Hsieh JJ
Cancer Med; 2014 Dec; 3(6):1485-92. PubMed ID: 25124064
[TBL] [Abstract][Full Text] [Related]
20. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.
DiNatale RG; Gorelick AN; Makarov V; Blum KA; Silagy AW; Freeman B; Chowell D; Marcon J; Mano R; Sanchez A; Attalla K; Weng S; Voss M; Motzer RJ; Russo P; Coleman JA; Reuter VE; Chen YB; Chan TA; Reznik E; Tickoo SK; Hakimi AA
Eur Urol Focus; 2021 Mar; 7(2):381-389. PubMed ID: 31813809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
